Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from Hold to Buy. Analyst Price Forecast Suggests 29.26% Upside As of December 23, ...

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) have been given an average rating of “Moderate Buy” by the five research firms that are covering the company, MarketBeat ...

HC Wainwright reiterated their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $50.

Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with a focus on Jornay PM expected to exceed $135 million in net revenue.

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...

The latest announcement is out from Collegium Pharmaceutical ( (COLL)). Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for ...

Collegium Pharmaceutical forecasts 2025 product revenues of $735-$750 million, with adjusted EBITDA of $435-$450 million. Collegium Pharmaceutical, Inc. has provided its financial guidance for ...

STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update.

Check the time stamp on this data. Updated AI-Generated Signals for Collegium Pharmaceutical Inc. (COLL) available here: COLL ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update. "In 2024, we executed on our ...

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...